ITP may lead to thrombocytopenia in newborns

A recent study showed maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopenia in newborns.

Much like fetal and neonatal alloimmune thrombocytopenia (FNAITFetal and neonatal alloimmune thrombocytopenia A rare condition in which a mother’s immune system attacks fetal platelets, leading to dangerously low platelet levels before and/or after birth.), maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopeniaThrombocytopenia A platelet count that is lower than normal. in newborns, according to a recently published study in the Journal of Obstetrics and Gynecology Research.

“ITP incidence is about 0.2% and constitutes 5% of all thrombocytopenia diagnoses in pregnancy,” the authors wrote. ”ITP is the most common cause of thrombocytopenia diagnosis before mid-pregnancy, whereas gestational thrombocytopenia occurs near-term,”

Learn more about FNAIT treatment and care

The authors aimed to assess the impact of maternal ITP on pregnancies. ITP is an autoimmune condition in which the immune system produces antibodies against its own platelets leading to thrombocytopenia. 

Researchers compared the pregnancies of 23 mothers with ITP with the pregnancies of 115 mothers without risk factors. Results showed that pregnancies in which the mother had ITP had a higher rate of fetal growth retardation (FGR), preterm delivery, and APGAR scores. 

In approximately 17% of pregnancies complicated with ITP, the maternal antiplatelet antibodies crossed the placenta, causing fetal thrombocytopenia. Three newborns with thrombocytopenia required treatment with intravenous immunoglobulinIntravenous immunoglobulin A treatment given to pregnant women with a history of FNAIT or known alloantibodies. IVIG reduces the immune reaction against fetal platelets. (IVIGIntravenous immunoglobulin A treatment given to pregnant women with a history of FNAIT or known alloantibodies. IVIG reduces the immune reaction against fetal platelets.). The authors found no correlation between newborn and maternal platelet counts. 

None of the newborns with thrombocytopenia suffered an Intracranial hemorrhageBrain bleed Bleeding inside the fetal brain, also known as an intracranial hemorrhage. In FNAIT, it's often caused by severe thrombocytopenia and can lead to long-term disability or death. , the most severe complication of fetal and neonatal thrombocytopeniaNeonatal thrombocytopenia Low platelet count in a newborn. In FNAIT, platelet levels may drop dangerously low within hours after birth.; these results correspond with previous studies that report an incidence below 1% in the context of maternal ITP.

Differences between ITP and FNAIT

Although both conditions lead to decreased platelet counts (thrombocytopenia), the mechanisms are quite different. 

FNAIT is an alloimmune disease in which the maternal immune system creates antibodies that target fetal platelet antigens inherited from the father. In ITP, on the other hand, maternal autoantibodies target mainly maternal platelets; fetal platelet destruction occurs in a minority of cases. 

ITP usually generates more moderate thrombocytopenia in fetuses and newborns than FNAIT. In ITP, the bleeding complications are experienced mainly by the mother, resulting in postpartum hemorrhageFetal hemorrhage Any bleeding that occurs before birth. In FNAIT, this usually results from extremely low platelet counts. and preterm delivery. 

“ITP in pregnancy is an important health issue because of the risk of fetal and maternal complications and adverse outcomes,” the authors concluded.